oftaquix 5 mg/ml silmatilgad silmatilgad, lahus
santen oy - levofloksatsiin - silmatilgad, lahus - 5mg 1ml 5ml 1tk
levofloxacin actavis silmatilgad, lahus
teva b.v. - levofloksatsiin - silmatilgad, lahus - 5mg 1ml 5ml 1tk
latanoprost/timolol elvim silmatilgad, lahus
sia elvim - timolool+latanoprost - silmatilgad, lahus - 5mg+50mcg 1ml 2.5ml 1tk
vizilatan duo silmatilgad, lahus
bausch + lomb ireland limited - timolool+latanoprost - silmatilgad, lahus - 5mg+50mcg 1ml 2.5ml 4tk; 5mg+50mcg 1ml 2.5ml 3tk; 5mg+50mcg 1ml 2.5ml 1tk
vizilatan silmatilgad, lahus
bausch + lomb ireland limited - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 1tk; 50mcg 1ml 2.5ml 3tk
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastilised ained - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
trodelvy
gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastilised ained - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - suguhormoonid ja immunoglobuliinid, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. vt lõigud 4. 4 ja 5.
latanoprost elvim silmatilgad, lahus
sia elvim - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 1tk
hemgenix
csl behring gmbh - etranacogene dezaparvovec - hemofiilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.